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Summary. In the Study of Myocardial Infarcüons Leiden, we
investigated the prevalence of three polymorphisms in the ct-
and ß-fibrinogen genes among 560 patients with a
myocardial infarction and 646 control subjects. Secondly,
we studied the relationships between these polymorphisms
and fibrinogen activity and antigen levels. The Taql, Haelll
and Bell polymorphisms in the fibrinogen gene were not
associated with myocardial infarction. As we found an
association of the rare B2 allele with fibrinogen levels and a
similar, but weak, effect for the rare H2 allele, we conclude
that a genetic propensity to high fibrinogen levels does not
affect the risk of myocardial infarction. This is evidence
against a causal role for fibrinogen levels in the aetiology of
myocardial infarction.
Keywords: fibrinogen, myocardial infarction, polymorph-
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Fibrinogen has been shown to be an independent predictor
of myocardial infarction. However, whether fibrinogen is a
causal risk factor or is elevated äs a result of either existing
atherosclerosis or the presence of other cardiovascular risk
factors remains unclear. Atherosclerosis is nearly always
present before the development of myocardial infarction. It
could well be that fibrinogen levels are elevated äs an acute-
phase reaction in the presence of atherosclerosis. A similar
Situation may exist with the presence of cardiovascular risk
factors. For example, smoking is associated with increased
fibrinogen levels and is simultaneously a risk factor for
myocardial infarction. As a result, fibrinogen levels may
appear to be associated with myocardial infarction but are,
in fact, elevated äs a consequence of smoking.
We studied the relationship between fibrinogen and
myocardial infarction indirectly. Several polymorphisms in
the genes encoding for the three separate chains of
fibrinogen have been described. In some studies, these
genotypes were associated with high levels of fibrinogen.
When these genotypes are associated with higher levels, one
would expect these genotypes to be present more often in
patients who had a myocardial infarction, but only if
fibrinogen plays a causal role in the development of
myocardial infarction. In this paper, we present the results
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of the population-based case-control Study of Myocardial
Infarcüons Leiden (SMILE) with respect to the relationship
between the Taql polymorphism in the ct-fibrinogen gene,
the Haelll (—455 G/A) and BcJI polymorphisms in the ß-
fibrinogen gene and myocardial infarction among 560 men
with a first myocardial infarction and 646 control subjects.
Secondly, fibrinogen levels were measured in the latter, and
an association with the presence of certain alleles was
looked for.
METHODS
Patients were men below the age of 70 years with a first
myocardial infarction. Controls were also men, frequency
matched to the patients in 10-year age groups, who had
undergone an orthopaedic Intervention and had received
prophylactic anticoagulants for a short period after this
Intervention. They did not have a history of myocardial
infarction and had not used anticoagulants for at least
6 months before participation in this study. Both patienls
and controls were born in the Netherlands. Füll details of
the SMILE study have been published elsewhere (Doggen
et al, 1998).
Morning fasting blood samples were drawn from the
antecubital vein into two Sarstedt Monovette tubes contain-
ing 0-106 mol/1 trisodium citrate. We separated the blood
sample into cells and plasma by centrifugation for 10 min at
3000 g at room temperature. Genomic DNA was extracted
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from the white blood cells by a salting-out method (Miller
et al, 1988) The Taql, Haelll and Bc/I polymorphisms were
genotyped after amplification of relevant DNA regions by
polymerase cham reaction (PCR) and digestion with the
appropnate restnction enzymes äs descnbed previously
(Thomas el al, 1991, 1995) Common alleles are coded äs
Hl, Tl and Bl, and the rare alleles are mdicated äs H2 T2
and B2 In the control subjects, fibrmogen activity was
measured m plasma using the Clauss thrombin time method
on a fully automatic coagulometer STA (Diagnostica Stago,
Boehringer Mannheim) Fibrmogen antigen levels were
measured with an enzyme-lmked immunosorbent assay
(ELISA)
Allele frequencies m patients and control subjecls were
compared by chi-square analysis A chi-square test was used
to compare the observed numbers of each genotype with
those expected for a population m Hardy-Wemberg
equilibnum An odds raüo (OR) with a 95% confidence
interval (95% CI) was calculated äs a measure of relative
risk Allele frequencies and means of fibrinogen are
presented with the 95% CI Analysis of vanance was used
to compare differences between means
RESULTS
The frequencies of the common alleles, the Taql, HaelH and
Beil polymorphisms, were 0 71,0 79 and 0 83, respectively,
with no difference between patients and control subjects
(Table I) The distnbution of genotypes was äs expected for a
population m Hardy-Wemberg equilibnum For persons
carrymg the T2 allele of the Taql polymorphism, the risk of
myocardial mfarction was not increased, with odds ratlos at
or close to umty, neither was the risk of myocardial
mfarction increased for carners of the H2 allele of the
Haelll polymorphism, nor for carners of the B2 allele of
the Bdl polymorphism
Among control subjects, carners of the T2 allele of the
Taql polymorphism had similar fibrmogen activity and
antigen levels compared with homozygous carners of the
common allele (Table II) Fibrmogen levels appeared to be
higher for heterozygous and homozygous carners of the H2
allele of the HaelH polymorphism, although not signifi-
cantly Antigen levels were higher lor carriers of the rare
allele of the Bc/I polymorphism compared with non-camers,
and a trend towards higher activity levels appeared äs well
DISCUSSION
Possession of rare alleles of the Taql polymoiphism m the ct-
fibrmogen gene and the Haelll and Bc/I polymorphisms in
the ß-fibrinogen gene was not a risk factor ior myocardial
mfarction Neither homozygous nor heterozygous carners of
rare alleles showed an increased or decreased risk compared
with homozygous carriers of common alleles As we
observed higher iibrinogen levels for carneis of the B2
allele of the Bc/I polymorphism, these data do not support a
causal role for fibrmogen in the aetiology of myocardial
mfarction
Our results are m agreement with those öl the Etüde Cas-
Temoms sur l'Infarctus du Myocarde (ECTIM) study, in
which genotype irequencies of the Haelll and Bc/I poly-
morphisms were also similar in patients with a myocardial
mfarction and in control subjects (Scarabm ei al 1993,
Behague et al, 1996) Homozygous carriers of the rare allele
of the Taql polymorphism were less frequent among patients
in Ireland, but not in France (Behague et al, 1996) The
frequency of the rare allele of the Haelll polymorphism was
virtually identical in patients with a myocardial mfarction
and in control subjects from Sweden (Green et al, 1993), m
an elderly population (van der Born et al, 1998), in
mdividuals who underwent coronary angiography (Gaide-
mann et al, 1997) and m men with and without ischaemic
Table I. Trequencies of the common alleles öl Taql Haelll and Bdl polymorphisms among 560 patients
and 646 control subjects and the nsk of myocardial mfarction foi heterozygous and homozygous cai ners
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Mean (CI) P value*
*P-vaIue of analysis of vanance compaimg levels between the three diffeient genotypes
Fibrmogen antigen (g/l)
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2 85 (2 75-2 96)
2 79 (2 40-3 18)




heart disease (Tybjasrg-Hansen ei al, 1997) To our knowl-
edge, only one study, which mcluded Italian patients with
familial myocardial mfarction, found an increased nsk for
carners of the rare allele of the Bdl polymorphism (Zito et al,
1997) Given the study srze of 560 patients and 646 control
subjects, we would have been able to detect a sigmficant
excess (P-value < 0 05) of allele carneis in patients vs
control subjects of about 8% (80% power), i e relative nsks
äs low äs l 5 Thus our xesults, which show no association
between polymorphisms and myocardial mfarction, are not
caused by lack of power
The irequency of the common allele of the Taql
polymorphism of 0 71 m our control subjecls was similar
to frequencies m healthy mdividuals from the UK, Ireland,
France and Finland, which ränge from 0 72 to 0 75
(Humphnes ei al, 1987 Thomas et al, 1995, Behague et al,
1996, Rauramaa et al, 1997) The same was true foi the
frequency of 0 79 of the common allele of the Haelll
polymorphism Frequencies ranging from 0 75 lo 0 81 have
been descnbed (Thomas et al, 1991, Green et al, 1993,
Scarabm et al, 1993, Behague et al, 1996, Gardemann et al,
1997, Tybjcerg-Hansen et al, 1997 Maigaghone et al,
1998, van der Born et al 1998, van't Hooft et al, 1999)
Agam the fiequency of the Bell polymorphism οί Ο 83 in
our control subjects was similar to that of other healthy
populations in which the frequency ranged fiom 0 83 to
0 85 (Thomas et al, 1995, Behague et al, 1996, Rauiamaa
et al, 1997, Zito et al 1997)
No association existed between the Taql polymorphism
and fibrmogen levels, either m our study or m other studies
(Humphnes ei al, 1987, Connor etal, 1992, Rauramaa et al,
1997) A trend towards increasing fibrmogen levels with the
rare allele of the Haelll polymorphism (—455 A) was found
(Thomas et al, 1991, Green et al, 1993, Tybjaerg-Hansen
et al, 1997, Gardemann et al, 1997, van der Born ei al,
1998, van'l Hooft etal, 1999), although the association was
not always sigmficant (Connor et al, 1992, Margaglione et al,
1998), äs m om own study Agam, the raie allele of the Bell
polymorphism seemed to be associated with increasing
fibrmogen levels in some studies (Humphnes et al, 1987,
Zito et al, 1997), but not all (Connor et al, 1992, Rauramaa
et al, 1997) We found that heterozygous carners had the
highest fibi mögen activity level although the association
was only sigmficant for the fibrmogen antigen level, not the
activity level Altogether, this suggests that there probably is
a weak relationship between the rare vanants in the ß-
fibnnogen gene and fibrmogen levels
We conclude that the Taql, Haelll and Bdl polymorphisms
in the fibrmogen gene are not related to myocardial
mfarction As we found an association of the B2 allele of
the Beil polymorphism with fibrmogen levels and a similar
but weak, effect for the H2 allele, we conclude that a genetic
piopensit3' to high fibrmogen levels does not affect the nsk of
myocardial mfarction This is evidence agamst a causal role
for fibrmogen levels in the aetiology of myocardial
mfarction
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